Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martina Baldin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analytical validation of the Mindray BC-75R Vet hematology analyzer and comparison with the Siemens Advia 2120i for application in dogs and cats

    by Martina Baldin, Sabrina Fasoli, Kateryna Vasylyeva, Chiara Agnoli, Maria Giulia Ferrari, Stefano Tropea, Michele Tumbarello, Elisa Brini, Francesco Lunetta, Elena Martoni, et al.

    The BC-75R Vet (Mindray Animal Medical) is a multi-species hematology analyzer that uses electrical impedance and SF-Cube technology (combining laser scatter, fluorescence, and 3-dimensional analysis) for CBC and reticulocyte analysis. We evaluated its analytical performance and compared it with the Advia 2120i (Siemens), a widely used analyzer in veterinary clinical pathology. CBCs were performed on EDTA-anticoagulated blood samples from 411 dogs and 225 cats submitted for routine testing. Analytical precision, linearity, carryover, and total observed error (TE obs ) were assessed according to ASVCP guidelines. We used a 2120i as the reference method and manual differential counts for WBC evaluation. RIs were calculated from 131 healthy dogs and 53 cats. The BC-75R Vet fulfilled the ASVCP requirements for repeatability (CVs < 5% for most variables) and linearity ( r > 0.97), with negligible carryover. TE obs values were within ASVCP allowable error limits, except for WBC types in QC material, which remained acceptable for in-clinic use. Agreement with the 2120i was acceptable for most RBC-related variables; however, systematic and proportional errors were found for mean corpuscular hemoglobin concentration (MCHC) in both species, and a systematic error for mean corpuscular volume (MCV) was found in dogs. Agreement for WBC and platelet counts was generally good, although discrepancies were noted for monocyte and mean platelet volume in both species. These differences likely reflect methodologic differences and known challenges in feline hematology. Despite these limitations, the BC-75R Vet met ASVCP standards and appears suitable for routine testing in dogs and cats. Manual smear review remains essential in selected cases.

  • Open Access

    Case Report: Clinicopathological findings of a cutaneous mast cell tumor in a young domestic meerkat (Suricata suricatta)

    by Marco Graziano Castaman, Margherita Orlandi, Martina Baldin, Maria Massaro, Mattia Ridolfi, Maristella Zambelli

    A 10-month-old female domestic meerkat ( Suricata suricatta ) was presented with a cutaneous nodule in the left axillary region. The animal was clinically healthy and radiographs showed no evidence of involvement of visceral organs. Based on fine-needle aspirate that revealed numerous well-differentiated mast cells, a mast cell tumor was suspected. Surgical excision was performed and the mass submitted for histologic examination. Histopathological findings showed a round cell tumor, with marked cellular atypia and moderate mitotic activity; Giemsa special staining revealed a large number of fine cytoplasmic metachromatic granules. Histological and histochemical findings confirmed the cytological suspicion of a mast cell tumor. Based on prognostic factors used in the canine species, immunohistochemistry with antibodies against Ki67 (a marker of cellular proliferation) and CD117 (a KIT receptor localization marker) revealed that 90% of the neoplastic population was positive for CD117 (with a membranous staining pattern), and the Ki67 index was 28. The patient did not show local recurrence and sign of distant metastases at the 10 months follow-up. Based on literature search no previous reports of mast cell tumour in meerkats were retrieved. Therefore, this case highlights a previously undocumented presentation of mast cell tumor in this species, contributing to the expanding knowledge of neoplastic conditions in exotic companion animals.

  • Open Access

    Beyond Individual Acute Phase Protein Assessments: Introducing the Acute Phase Index (API) as a Prognostic Indicator in Dogs with Malignant Neoplasia

    by Martina Baldin, Maria Elena Gelain, Giacomo Marolato, Silvia Bedin, Michele Berlanda, Manuela Zanetti, Filippo Torrigiani, Alessia Giordano, Pierangelo Moretti, Donatella Scavone, et al.

    Acute phase proteins (APPs) are part of the innate immune response, changing during inflammation. An Acute Phase Index (API) is a calculated value that combines multiple APPs. In human medicine, the introduction of APIs has improved outcome monitoring. In veterinary medicine, APIs have been evaluated in livestock and dogs with Leishmaniasis. This study aimed to calculate an API and evaluate its significance in cancer-bearing dogs. Sera were collected from 55 dogs, which were classified by neoplastic category and survival times (> or < than 30 and 90 days). For 32 dogs, multiple samples were available. The API included C-Reactive Protein (CRP) and haptoglobin as positive APPs, and albumin and Paraoxonase-1 (PON-1) as negative APPs. An alternative API excluding PON-1 was calculated. PON-1 levels were lower in round-cell tumors, suggesting increased oxidative stress. Moreover, API increased and PON-1 activity decreased in the last sample in dogs that died before the end of the study. Dogs with shorter survival times showed increased APIs and CRP levels. APIs with and without PON-1 greater than 0.049 and 0.202 at the first sampling were associated with a 3.7- and 4.4-fold higher probability of death, respectively. These results suggest a potential prognostic value of API in dogs with neoplasia.